CT Governor Attends Groundbreaking For Pfizer Drug Development Facility In New London

Connecticut Governor John G. Rowland joined a host of state and local dignatories yesterday in a groundbreaking ceremony for a 400,000 square-foot global drug development facility for Pfizer in New London.

The facility is part of Pfizer's worldwide research & development expansion, which also includes 1.5 million square-feet of new research space in Groton, CT; Sandwich, England and Nagoya, Japan. Pfizer's expansion to the 24-acre New London site, directly across the Thames River from its R&D headquarters, is part of a larger development plan to revitalize New London's historic waterfront. This initiative is being led by a collaborative team of The State of Connecticut, The City of New London, The New London Development Corporation and Pfizer.

"This is an exciting time of unprecedented opportunity on many fronts," said Dr. George M. Milne, Jr., Pfizer Central Research president. "Scientifically, we have capabilities to probe diseases and discover and develop tomorrow's medicines. At Pfizer we have a pipeline of novel drug candidates that is unprecedented for the company and among the most bountiful in the pharmaceutical industry. And we are delighted to be building our new world class facility to develop these drugs here in New London, joining the city, the state and the NLDC in their commitment to this community and our state's biotechnology industry."

For more information: Kate Robins, tel: 860-441-5448 or John Stratton, tel: 860-441-3144, Pfizer Inc.